ALXN1830
Sponsors
Alexion Pharmaceuticals, Inc.
Conditions
Generalized Myasthenia GravisHealthyPemphigusPemphigus FoliaceusPemphigus VulgarisWarm Autoimmune Hemolytic Anemia
Phase 1
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
TerminatedNCT03075878
Start: 2018-01-10End: 2019-08-06Updated: 2020-05-13
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
TerminatedNCT03075904
Start: 2017-07-18End: 2019-01-16Updated: 2020-02-05
A Study of ALXN1830 in Healthy Adult Participants
TerminatedNCT04730804
Start: 2021-03-17End: 2022-01-04Updated: 2024-09-19
A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
TerminatedNCT05254613
Start: 2019-11-12End: 2021-01-22Updated: 2024-03-22
Phase 2
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
WithdrawnNCT04256148
Start: 2021-07-31End: 2023-04-30Updated: 2020-07-13
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
WithdrawnNCT04956276
Start: 2022-01-01End: 2024-07-31Updated: 2022-02-11
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
WithdrawnNCT04982289
Start: 2022-01-01End: 2024-01-31Updated: 2022-02-11